Healthcare / BiotechnologyBrussels
$5.20
+0.00 (+0.00%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 15%
FCF escenarios
weak_data · normalized FCF $-1.0M · quality 33.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
37/100
D
Piotroski
6/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$22M
P/E
12.1x
↓EV/EBITDA
7.5x
↓ROE
15.3%
↑Gross Margin
32.9%
↓Debt/Equity
1.58
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+12.3%
FCF CAGR
—
FCF margin
5.0%
FCF / Net income
1.36x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $49.9M · net income $1.8M · FCF $2.5M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $49.9M | $49.9M | $45.1M | $40.6M | $35.3M |
| Net Income | $1.8M | $1.8M | $546000.00 | $-709000.00 | $-5.6M |
| EBITDA | $4.8M | $4.8M | $3.8M | $2.0M | $-1.3M |
| EPS | 0.43 | 0.43 | — | -0.17 | -1.30 |
| Gross Margin | 32.9% | 32.9% | 33.1% | 33.3% | 34.7% |
| Operating Margin | 5.4% | 5.4% | 3.1% | 0.0% | -4.7% |
| Net Margin | 3.7% | 3.7% | 1.2% | -1.7% | -15.8% |
| Balance Sheet | |||||
| Debt/Equity | 1.58 | 1.58 | 2.02 | 1.93 | 1.44 |
| Current Ratio | 1.41 | 1.41 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $2.5M | $2.5M | $-1.0M | $-4.8M | $-117000.00 |
| Returns | |||||
| ROE | 15.3% | 15.3% | 5.3% | -7.2% | -52.4% |
| Valuation | |||||
| P/E | 12.09 | 12.09 | — | — | — |
| EV/EBITDA | 7.50 | 7.50 | 11.85 | 25.43 | — |
| P/B | 1.82 | 1.82 | 2.74 | 3.69 | 5.91 |
| Growth & Yield | |||||
| Revenue Growth | 10.6% | 10.6% | 11.3% | 15.0% | — |
| EPS Growth | — | — | — | 87.3% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
2.0%
EPS terminal req.
$0.46
Spread vs growth
8.6%
5Y implied EPS CAGR
5.1%
EPS terminal req.
$0.56
Spread vs growth
5.5%
10Y implied EPS CAGR
7.5%
EPS terminal req.
$0.90
Spread vs growth
3.1%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+10.6%
Start / end P/E
n/dx → n/dx
EPS bridge
n/d → 0.43
Residual
+10.6%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.